Project Grant R01EB038025
Award Date 8/1/25
Completion Date 4/30/29
Dollars Obligated $332K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
- This federal Project Grant award of $472,921.00, awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research to investigate the role of the CR1 signaling pathway in regulating cellular plasticity and breast cancer progression. The University of Utah is conducting this research, which aims to understand the molecular mechanisms by which CR1 mediates stress-adaptive cell state changes in breast cancer cells and their surrounding microenvironment. The project...
- This Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $219,491 to Emory University to conduct research on mapping the origin of HER2 plasticity in breast cancer. The research aims to gain mechanistic insight into how HER2 expression is dynamically regulated in breast cancer, and explore whether this dynamic HER2 expression can be augmented to improve patient outcomes. The project will employ characterized cell culture...
- This federal Project Grant award of $584,510.00, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports the development of advanced spatial transcriptomics and proteomics technologies for studying tumor microenvironments. The award enables the University of Colorado-Denver to implement new imaging techniques and computational approaches to enhance the capabilities of its Human Immune Monitoring Shared Resource (HIMSR). This will allow...
- This federal Project Grant award of $154,000.00 was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to the University of Utah. The project, titled "One Cell, One Cancer: A Novel Genetic Approach to Mouse Models of Human Cancer Initiation," aims to develop a novel dual-recombinase system, termed "Flp-out," to induce oncogenic mutations in single cells for improved modeling of pancreatic ductal adenocarcinoma (PDAC) initiation...
- The University of Utah has been awarded a $1,128,787 Project Grant by the Defense Health Agency, an agency of the U.S. Department of Defense, under the Military Medical Research and Development program (CFDA 12.420). The grant is for a 3-year project titled "OPTIMIZING QUANTITATIVE PHASE IMAGING FOR PREDICTING BREAST CANCER THERAPY RESPONSE," with a performance period from January 15, 2024 to January 14, 2027. The funded research aims to develop and evaluate advanced quantitative phase...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $218,886 to The Trustees of Columbia University in the City of New York to develop a new light-activated technology for targeted protein degradation in cancer cells. The project aims to optimize a photocatalytic system that can selectively degrade cancer proteins, such as the immune checkpoint receptor PD-1 and the oncogenic phosphatase SHP2, using deep red light to initiate targeted...
- The University of Utah will receive $1.3 million under a four-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from July 2022 to June 2026 to develop functional precision oncology approaches to predict, prevent, and treat early metastatic recurrence of triple-negative breast cancer. Through basic, applied, and advanced biomedical research, the Military Medical Research and Development...
- This Project Grant award of $1,539,469.00 from the Defense Health Agency was provided to the University of Utah under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the "Molecular Crosstalk Between Estrogens and Progestogens in Endometrial Cancer." The award will fund this biomedical research project from September 1, 2023 to August 31, 2026. The University of Utah has an extensive track record of collaborating with government agencies on...
- This $613,125 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period of 3 years from February 2025 to January 2028. The research aims to advance innovative therapeutic approaches...